Iroko Pharmaceuticals, LLC

Quick facts

Phase 3 pipeline

• Diclofenac Test (lower dose) · Pain Management / Rheumatology
  Diclofenac is a nonsteroidal anti-inflammatory drug (NSAID) that inhibits cyclooxygenase (COX) enzymes to reduce prostaglandin synthesis and decrease inflammation and pain.
• Diclofenac Test (upper dose) · Pain Management / Rheumatology
  Diclofenac is a nonsteroidal anti-inflammatory drug (NSAID) that inhibits cyclooxygenase (COX) enzymes to reduce prostaglandin synthesis and decrease inflammation and pain.

Phase 2 pipeline

• Diclofenac Capsules high dose · Rheumatology
  Diclofenac works by inhibiting the enzyme cyclooxygenase (COX), which is involved in the production of prostaglandins, leading to reduced inflammation and pain.
• Diclofenac Capsules low dose · Rheumatology
  Diclofenac works by inhibiting the enzyme cyclooxygenase (COX), which is involved in the production of prostaglandins, leading to reduced inflammation and pain.
• Indomethacin Capsules high dose · Rheumatology
  Non-selective COX-1 and COX-2 inhibitor
• Indomethacin Capsules low dose
• Naproxen Test

Competitive intelligence

For the full portfolio CI brief — phase mix, recent regulatory actions, upcoming PDUFA dates, patent timeline, class-overlap with competitors:

• Iroko Pharmaceuticals, LLC portfolio CI brief
• Iroko Pharmaceuticals, LLC pipeline updates RSS